157 related articles for article (PubMed ID: 34209595)
1. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
Boriani G; De Caterina R; Manu MC; Souza J; Pecen L; Kirchhof P
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209595
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
3. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study.
Kirchhof P; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Lopez-de-Sa E; Monteiro P; Fronk EM; Lamparter M; Laeis P; Smolnik R; Steffel J; Waltenberger J; Weiss TW; De Caterina R;
Int J Cardiol; 2024 Aug; 408():132118. PubMed ID: 38697397
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
Gwechenberger M; Barón-Esquivias G; de Vries TAC; Siller-Matula JM; Manu MC; Souza JAG; Wienerroither S; Pecen L; de Groot JR; De Caterina R; Kirchhof P;
JACC Adv; 2024 Apr; 3(4):100880. PubMed ID: 38939675
[TBL] [Abstract][Full Text] [Related]
6. [Oral anticoagulation with Edoxaban for stroke prevention in patients with atrial fibrillation: Analysis of 1-year follow-up data of routine clinical practice in Germany, Austria and Switzerland (DACH) from the ETNA-AF registry].
Dinshaw L; Steffel J; Götte A; Weiss TW; Waltenberger J; Kirchhof P
Dtsch Med Wochenschr; 2024 Jul; ():. PubMed ID: 38959945
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
8. Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
Choi EK; Choi JI; Park HS; Hwang GS; Joung B; Kim JY; Kim DH; Shin DG; Park HW
J Arrhythm; 2023 Aug; 39(4):546-555. PubMed ID: 37560283
[TBL] [Abstract][Full Text] [Related]
9. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
De Caterina R; Kim YH; Koretsune Y; Wang CC; Yamashita T; Chen C; Reimitz PE; Unverdorben M; Kirchhof P
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546442
[TBL] [Abstract][Full Text] [Related]
10. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF Program.
Choi JI; Kiatchoosakun S; Jiampo P; Tse HF; Soo YOY; Wang CC; Lee CH; Pecen L; Unverdorben M; De Caterina R; Kirchhof P
Circ Rep; 2024 Mar; 6(3):86-93. PubMed ID: 38464984
[No Abstract] [Full Text] [Related]
11. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
12. Use of edoxaban in clinical practice: Comparison of data from the Spanish population in the ETNA-AF-Europe registry.
Barón-Esquivias G; Roldán Rabadán I; García Quintana A; Cerezo Manchado JJ; Antorrena Miranda I; Gómez-Barrado JJ; Pérez Paredes M; Santas E; Pindado Rodríguez J; Muñoz-Robles JA; Oliver-Miñarro D; Santamaría A;
Future Cardiol; 2020 Sep; 16(5):469-480. PubMed ID: 32228182
[No Abstract] [Full Text] [Related]
13. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.
de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
Neth Heart J; 2021 Mar; 29(3):158-167. PubMed ID: 33411231
[TBL] [Abstract][Full Text] [Related]
14. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.
Choi EK; Lin WS; Hwang GS; Kirchhof P; De Caterina R; Chen C; Unverdorben M; Wang CC; Kim YH
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830618
[TBL] [Abstract][Full Text] [Related]
15. [One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe].
Ameri P; Riva L; Toma M; Di Pasquale G; De Caterina R
G Ital Cardiol (Rome); 2020 Jul; 21(7):546-557. PubMed ID: 32555574
[TBL] [Abstract][Full Text] [Related]
16. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
Diemberger I; Fumagalli S; Mazzone AM; Bakhai A; Reimitz PE; Pecen L; Manu MC; Gordillo de Souza JA; Kirchhof P; De Caterina R
Europace; 2022 Oct; 24(9):1404-1411. PubMed ID: 35512229
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
[TBL] [Abstract][Full Text] [Related]
18. Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48.
Berg DD; Ruff CT; Jarolim P; Giugliano RP; Nordio F; Lanz HJ; Mercuri MF; Antman EM; Braunwald E; Morrow DA
Circulation; 2019 Feb; 139(6):760-771. PubMed ID: 30586727
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.
Yamashita T; Koretsune Y; Nagao T; Shiosakai K
J Arrhythm; 2020 Jun; 36(3):395-405. PubMed ID: 32528563
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2.
Fernandez MM; Wang J; Ye X; Kwong WJ; Sherif B; Hogue S; Sherrill B
SAGE Open Med; 2015; 3():2050312115613350. PubMed ID: 27092254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
